Pmv Pharmaceuticals, INC 8-K filings

PMV Pharmaceuticals announced second quarter 2026 financial results, highlighting the completion of patient enrollment for its Phase 2 PYNNACLE trial and planning a 2027 NDA submission for rezatapopt.

PMV Pharmaceuticals stockholders elected two Class III directors, approved executive compensation, and ratified Ernst & Young LLP as auditors.

PMV Pharmaceuticals announced first quarter 2026 financial results, highlighting Orphan Drug Designation for rezatapopt and positive clinical trial updates, with a planned NDA submission in Q1 2027.

PMV Pharmaceuticals announced full year 2025 financial results and provided a corporate update, highlighting progress in its PYNNACLE trial and an anticipated NDA submission for rezatapopt.

PMV Pharmaceuticals announced its third quarter 2025 financial results and positive clinical data for rezatapopt, planning an NDA submission for ovarian cancer in Q1 2027.

PMV Pharmaceuticals announced promising interim Phase 2 data for its monotherapy rezatapopt in solid tumors with a TP53 Y220C mutation, planning an NDA submission for platinum-resistant/refractory ovarian cancer by Q1 2027.

PMV Pharmaceuticals reported its second quarter 2025 financial results, highlighting a cash runway into late 2026 and upcoming interim data from its Phase 2 PYNNACLE clinical trial.

PMV Pharmaceuticals, Inc. announced that its stockholders voted against the non-binding advisory proposal to approve executive compensation, while re-electing two Class II directors and ratifying Ernst & Young LLP as its independent auditor.

PMV Pharmaceuticals announces Q1 2025 financial results, highlighting progress in the PYNNACLE clinical trial and a cash runway to the end of 2026.

PMV Pharmaceuticals announces full year 2024 financial results, highlighting progress in the PYNNACLE clinical trial and a cash runway to the end of 2026.

PMV Pharmaceuticals announced its third quarter 2024 financial results, highlighting progress in its PYNNACLE clinical trial and a collaboration for a new Phase 1b study.

PMV Pharmaceuticals terminated its existing lease, provided an update on its PYNNACLE clinical trial, and announced its second quarter 2024 financial results.

PMV Pharmaceuticals held its 2024 Annual Meeting, electing two Class I directors and approving executive compensation and the ratification of its accounting firm.

PMV Pharmaceuticals reported its first quarter 2024 financial results, highlighted by the first patient dosed in the Phase 2 portion of the PYNNACLE trial and a cash runway extending to the end of 2026.

PMV Pharmaceuticals announced its full year 2023 financial results, highlighted by progress in its rezatapopt clinical program and an extended cash runway to the end of 2026.

PMV Pharmaceuticals is reducing its workforce by approximately 30% to prioritize the development of PC14586 and extend its cash runway.